initi buy differenti view
expect estim rise
lead manufactur small molecul api see cambrex benefit
increas api outsourc acquisit play anoth trend
suppli chain simplif fewer broadli capabl vendor believ
gilead analysi cbm top custom differenti posit
valuat gap narrow remain discount think
close initi buy
softer land believ cbm revenu beyond
hold better market fear analysi show closer tie european hcv
franchis treatment infect patient measur new patient
start fairli stabl mani year cbm revenu
believ market expect declin believ rate
declin teen take revenu
industri trend favor api bundl outsourc hype around biolog
give impress pipelin shift complet larg molecul biolog
grow faster small molecul still repres approv small molecul
api outsourc uniqu rise massiv intern sponsor invest biolog
capac addit industri highli fragment larger integr player
patheon led industri outsourc mandat new drug approv
acquisit posit cbm cross-sel recent year lead cmo
broaden servic portfolio patheon across api drug substanc finish dose
multi-finish dose invest qualiti system receiv outsourc
mandat add finish dose cbm alreadi strong api capabl establish
qualiti track record estim accret manag provid
guidanc call believ analyst wait guidanc updat
estim thu consensu estim look low
balanc sheet still under-lev estim cbm net debt
pro-forma adj ebitda manag room make anoth acquisit
similar size reason leverag
valuat gap narrow close cbm trade discount
ebitda revenu declin cbm largest client present risk form revenu
headwind ebitda margin pressur visibl challeng multipl new product
replac api howev consensu estim look overli conserv rel
risk valuat still present margin safeti
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
cambrex revenu outperform consensu result
gilead-rel revenu declin slowli consensu
ebitda margin declin hit
revenu replac sever new compound
fold legaci cbm return expans bp
increas gener penetr pharma relianc
western cmo allow ex-gilead busi grow
grow annual par fdf market
ebitda margin pressur transit
new pipelin molecul pressur mitig
moder declin
consensu number appropri reflect
acquisit current account treatment
diversifi revenu base build innov pipelin
halo growth outpac fdf market grow
graduat larg innov molecul
pipelin combin freed capac gilead
cross-sel opportun legaci cambrex drive
updat guidanc announc accret
synergi
ebitda margin grow result
increment gener appli debt reduct
gilead busi declin faster anticip
weaker gilead busi lead underutil facil
pressur ebitda margin
minim cost synergi realiz acquisit
market revalu compani one low/no growth
compress multipl
page
pleas see import disclosur inform page report
initi coverag cambrex corpor cbm buy rate
price target cambrex corpor lead contract
manufactur activ pharmaceut ingredi market segment cbm produc
high return invest capit low rang benefit outsourc growth
exist market expand address market includ finish dosag
form cbm play grow outsourc api manufactur
believ cbm gilead revenu declin softer land
market fear investor greatest concern cambrex revenu concentr
top client gilead cambrex produc sofosbuvir gilead hepat franchis
declin investor fear declin acceler pressur revenu ebitda
beyond consensu fear evidenc cbm discount valuat ev/ebitda
price-to-earnings analysi show cbm suppli tie gilead european franchis
patient volum expect steadier sever year
industri trend favor outsourc small molecul manufactur
steep brief drop fda product approv improv markedli
current fda leadership see competit pro-busi approach control drug
price inclin acceler approv increas share approv drug
owned/sponsor smaller compani lack intern manufactur capac
despit biolog hype small molecul approv percent total drug approv
held steadi around final larg pharma shift intern capit
invest larg molecul product small molecul capac mainten
mean inclin outsourc small molecul manufactur
revenu diversif away gilead expans cbm address market
includ fdf custom increasingli attract broad capabl provid
activ sponsor seek simplifi streamlin suppli chain evidenc
share leadership cdmo broad capabl patheon
think acquisit fit nice trend better
posit cambrex gain share
price target base combin rel valuat
price-to-earnings ev/ebitda dcf compar peer
among cmo trade ebitda estim ep
estim current cbm trade ebitda ep
carri lower leverag attribut discount revenu concentr
declin well busi mix market market cap trade volum sell-
side coverag view cbm result benefit stabl eu hcv sale
growth innov accret concentr wane
expect ep growth valuat expans toward
larger-than-expect roll-off revenu particularli guidanc inabl
scale ex-gild innov revenu mid-teen capac underutil lead
margin compress overpay acquisit outsourc trend revers
page
pleas see import disclosur inform page report
believ investor
concentr gild overal start
declin miss nuanc
disproportion weight
europ
view market discount cbm revenu tie gilead heavili base
declin patient start hcv busi believ investor
concentr gilead overal start declin miss nuanc cbm gilead-
relat revenu seem disproportion weight gilead europ
patient start roughli flat past month govern control
budget mean protract treatment/cur curv
three data point tie sofosbuvir european busi
found three key data point suggest cambrex manufactur sofosbuvir
primarili europ importantli cbm preclud discuss contract
cambrex manag impli confer call includ
ship larg innov product intern
initi post-deal call gild sovaldi still undergo
trial initi get clear pictur
product go howev subsequ call clear fact
produc product ship oversea
cbm first announc suppli deal larg innov drug
began ramp commerci product start
next three year compani invest
two expans charl citi plant support new product start
cbm record larg uptick domest export roughli equal size
growth sale see chart meant cbm like
manufactur ship larg quantiti intern
time cbm sale europ also jump roughli size
export cbm europ sale rose
meanwhil north america sale actual fell
perhap indic cbm shift capac charl citi
plant domest project sofosbuvir europ
page
pleas see import disclosur inform page report
chart chang cambrex sale time
furthermor gilead own lone european manufactur facil cork ireland
design solid dose tablet manufactur qualiti control product packag
label number drug includ sovaldi harvoni epclusa antivir
unit take api finish tablet packag label readi final
product distribut throughout eu intern market gilead
describ facil serv eu intern market believ
reason facil gener exclud america asia develop
countri two reason
use two manufactur plant san dima la vern california
manufactur packag label hcv drug america pacif
sign deal india-bas contract manufactur manufactur
distribut develop countri like outsourc dosag form
manufactur geographi avoid signific capit outlay
emerg perhap less certain market believ contract cover
rest world exclud europ
recap view suppli chain cbm manufactur sofosbuvir api charl
citi cbm ship product cork ireland record sale ship
quantiti take cbm api along third-parti api manufactur
finish hcv product product distribut european
base analysi demand
volum cbm api
depend european
patient start
opinion diverg current
base demand volum cbm api depend
european patient start opinion diverg current bear thesi
distinct import europ util trajectori differ
us japan rest world believ eu util thu volum
alreadi begin show sign flatten declin gradual
page
pleas see import disclosur inform page report
valu sale gildchang domest exportschang european sale cbm
gilead first hcv drug sovaldi approv us decemb follow
quickli approv eu januari prior hcv treatment
gener expens somewhat effect chronic medic
requir patient stay drug news broke across medic
commun gilead come market once-a-day pill cure hcv
rate high cours three month gener excit among
provid patient alik doctor began wareh sick patient new
therapi sovaldi took quickli enrol thousand patient
approv harvoni came less year later us eu greenlight
medicin octob novemb respect treatment combin
sofosbuvir found sovaldi anoth antivir ledipasvir boost
cure rate even higher elimin need use side-effect-induc ribavirin allow
patient low diseas level patient complet
treatment week instead standard
tale contin
great scientif medic leap forward mediocr busi
model patient cure diseas would longer requir drug
result patient start crest fallen sinc world-wide us patient start
fallen dramat region eu face smaller declin eu
start environ differ coupl reason
us payer mix highli weight toward commerci mean
long patient insur high likelihood abl
receiv drug combin formulari inclus patient
access program coupon eu single-pay system set budget
limit rate patient treat gener start sickest
stamped door drug got approv
us also treat patient earli stage diseas oppos
eu select treatment function
point payer gener lead cultur us treat patient
liber evidenc fibrosi score differ
two region see chart
page
pleas see import disclosur inform page report
pill volum patient start moder declin
late gilead secur approv harvoni prescrib began put
patient cheaper treatment becam standard care
patient hcv patient eu low diseas level cut
pill count select patient manag note call
patient regimen number pill need averag
start fell reduc demand drug supplier
trend revers cours juli gilead epclusa approv use
genotyp without ribavirin epclusa pan-genotyp treatment
target patient otherwis would take
sovaldi ribavirin cure addit price discount
harvoni save need perform genotyp test encourag util
despit competit lead declin sale start think pill per start
rose time frame moder api declin mid-to-high singl digit see tabl
like larger concentr harvoni gilead report
start number lower proport harvoni start
page
pleas see import disclosur inform page report
hcv yoy pt pt cbm
estim start ldd rang pill volum
less hsd rang believ pill volum growth like
converg patient start growth neg hsd rang recent period
show start falloff slow msd-hsd rang see
tabl believ flatten start translat moder declin cbm
outsourc penetr drug
declin precipit shown
chart outsourc small
molecul api rise
industri trend favor outsourc small
cdmo small molecul api arguabl goldilock posit ye larg
molecul drug approv increas faster small molecul approv
expect continu howev larg molecul capac grown dramat
accord pharmsourc larg pharma spent period
devot larg part build drug substanc manufactur thu outsourc
penetr drug substanc aka larg molecul api declin precipit
shown chart
hand small molecul capx invest wane time frame
pharma manufactur focus build expertis reduc uncertainti
around less-refin process drug substanc manufactur becom
comfort outsourc matur harden process around api manufactur
result api outsourc grow
final small molecul approv continu grow may come surpris
shift biolog happen gradual approxim
global biopharma sale come biolog phase pipelin repres
biolog rise rang preclin pipelin thu even
year proport would suggest rel even split approv
product biolog drug larg small molecul grant price
larg molecul might shift revenu somewhat rapidli
page
pleas see import disclosur inform page report
bottom line small molecul approv grow albeit slower pace small
molecul api outsourc increas augment growth rate wherea biolog
outsourc decreas
drug approv solid expect improv
slow year new drug approv bounc nda
nme year-to-d fda approv nme compar time
last year pace solid quicken
chart fda approv nda nme bla
outlook continu strong new product introduct encourag
activ commerci ind initi new drug applic continu rise serv
basic measur industri throughput innov
page
pleas see import disclosur inform page report
final fund support develop innov strong biotech
compani rais money across matur stage evidenc strong vc
chart ttm global biotech fund record
chart biotech balanc sheet
fda gov jefferi
catalyz combin
custom concentr
highly-frag industri
custom increasingli want
fda gov jefferi
cambrex hunt acquisit time devot resourc
inorgan strategi vet deal cambrex hasnt highli acquisit last
hand year push think acquisit interest catalyz
combin larg custom concentr declin cash rich balanc
sheet highly-frag industri custom increasingli want simplifi
suppli chain fewer high qualiti near one-stop shop
see three key benefit transact first calcul ep accret
halo first full calendar year compani
manag comment accret adjust consolid guidanc
transact plan earn
second addit revenu cambrex base acceler
diversif away high concentr gilead manag disclos
concentr annual revenu
vast major come singl product believ sofosbuvir
account concentr total revenu respect
import amount direct gilead hcv franchis declin
drag cambrex revenu help plug hole
anticip revenu total revenu
final halo focu finish dosag form manufactur expand cbm address
market contract manufactur adjac work custom
cambrex serv none serv fdf biopharma
industri show increas propens outsourc work larger cdmo
broad capabl patheon and/or led leagu
page
pleas see import disclosur inform page report
tabl last three year cambrex strategi compar
close patheon servic across api finish dosag form patheon also
compet drug substanc market cambrex serv
prior cbm last acquir pharmacor north carolina septemb
though small transact ebitda cambrex high
point call expand cambrex abil engag client develop
project feeder larg scale commerci manufactur busi
transact integr well contribut three compound cambrex late-stag
product pipelin addit cambrex recent commit invest add
job nearli doubl oper multipl year
past three year patheon top rank
outsourc nda approv secur contract nda approv
compar patheon compani capabl allow take
product start finish increas attract pharma compani
wish go asset-light increas use outsourc
though slightli differ approach patheon build broad
servic platform serv client across client strateg engag
rather tactic molecul molecul stage stage rfp approach
industri follow past patheon servic span develop api drug
substanc dosag form almost anyth custom need
avoid api build broad platform dosag form capabl enabl
pharma pan-dosag form vendor choic
highlight cbm take signific step becom end-to-end
acquisit fdf capabl complement legaci cbm api
capabl halo custom overlap exist cambrex custom
make potenti project cross-sel allow cambrex take
fulli outsourc project
cambrex contract manufactur organ manufactur activ
pharmaceut ingredi api recent final dosag innov
cambrex current produc product three categori includ innov drug
gener control substanc add fourth describ three
segment detail
cambrex manufactur api intermedi innov pharmaceut compani
novel therapi compani gener roughli sale segment
total revenu come custom gilead scienc
page
pleas see import disclosur inform page report
manag state expect see significantli reduc volum
product cbm contract includ defin minimum
volum agreement minimum volum final year
current contract gilead busi slow growth yoy
manag describ ex-gilead innov grow quickli expect mid-to-
high teen growth portion current product late-stag pipelin
expect grow come year product manag
expect product gener product gener
product gener
chart revenu contribut segment
cambrex manufactur gener product equat sale
revenu product four produc segment
revenu remain individu contribut less
focu nich market target strategi cambrex target market
less crowd addit gener api later stage develop
file anda cambrex well-posit grow segment take share
due chang prefer gener pharma compani toward western
supplier increas gener adopt develop market outsid us
compani strategi also call expand geograph develop market
brazil japan russia mexico well penetr overal gener
market api fdf supplier clear cambrex strategi date
gain approv manufactur gener api sell commerci gener
player take product market
cambrex sold control substanc api portfolio product
product classifi schedul ii market
higher barrier entri product must manufactur us licens
manufactur insul domest manufactur low-cost competit
limit product product quota system cambrex grown
segment low-to-mid teen annual past three year
page
pleas see import disclosur inform page report
importantli emphasi non-opi pain adhd market former size
grow
cambrex recent acquir juli lead finish dosag form custom
develop manufactur provid product develop commerci
manufactur servic innov gener pharmaceut market
manufactur varieti dosag form includ oral solid liquid steril ointment
gel suppositori bulk powder gener revenu
ebitda previou twelv month
two state-of-the-art facil locat whippani new jersey mirabel
quebec oper busi approv sku activ product
develop project activ custom total capac billion
unit solid dose liter liquid unit suppositori kg semi
solid kg steril ointment kg bulk powder
financi accret cbm ep ep see
tabl number assum cbm borrow purchas price
cambrex primari large-scal manufactur facil charl citi karlskoga
locat locat produc primarili innov api itali locat
compani primari gener api product facil germani estonia much
smaller technic support lab us high point pharmacor acquisit serv
smaller scale synthesi develop servic locat consist cambrex
strategi engag client earlier clinic develop phase
page
pleas see import disclosur inform page report
tabl cambrex manufactur capac size
page
pleas see import disclosur inform page report
page
pleas see import disclosur inform page report
exhibit paullo milan itali commerci gener brand api advanc intermedi
exhibit high point north carolina earli phase intermedi api manufactur
begin manag took cautiou stanc revenu guidanc
state saw flat yoy revenu growth overal midpoint met would
end long seven-year run hsd dd growth enjoy sinc far
page
pleas see import disclosur inform page report
